America’s innovation ecosystem powers new medicines, 5M+ jobs and $1.6T in economic impact. But we need smart policy—IP protection, regulatory clarity and market-based payment—to thrive. Let’s build a healthier, more resilient future. Learn more at

Vaccines show what U.S. biopharma leadership can achieve—from eliminating deadly diseases to preparing for future threats. Maintaining that edge means supporting policies that reward innovation and risk-taking. This #NIAM, explore what makes it possible:

The life sciences industry leads in investing in American innovation. Congratulations to Pascal Soriot and @AstraZeneca on the $50B expansion of their R&D footprint in the U.S. This bold move is another great example of how our industry is bringing groundbreaking medicines to.

Congratulations to Chris Viehbacher and the @biogen team on their major investment to expand their manufacturing capabilities in North Carolina’s Research Triangle Park—one of the nation’s most innovative life sciences hubs. This commitment will accelerate the development of.

RT @PhRMA: America’s future in medical innovation depends on what we build today. Across the country, biopharmaceutical companies are inves….

Yesterday, we recognized our 2024 #WorkingForCures champions and celebrated their accomplishments. Congratulations and thank you again for your tireless dedication to our industry.

Our 2024 Working for Cures champions are here today in DC to receive their awards in front of their industry colleagues. These champions have gone above and beyond to support the work our industry does for patients, conducting facility tours with members of Congress, elevating

RT @PhRMA: We’re proud to welcome @SumitomoPharma as the newest member of PhRMA!. They join PhRMA as our fourth new member in the last two….

RT @PhRMA: Foreign governments pay less than they should for innovative medicines, relying on U.S. investment to drive progress. This fo….

New data shows abuse of the #340B program cost taxpayers $6.5 billion in lost Medicaid rebates in 2024 alone. It’s time for Congress to address this multi-billion-dollar burden on taxpayers.

The U.S. is the only country where entities that don’t make medicine, like #PBMs, #340B hospitals and others, get half of every dollar spent on medicines. Meanwhile, foreign countries freeride on U.S. innovation, increasing costs for American patients. The reality is government.

Other wealthy countries underpay for innovative medicines—paying 60% less on average for brand medicines than they should. This is known as foreign freeriding, and it drives up costs for U.S. patients. It’s time to make other countries pay their fair share. More from @NPLB_org.

RT @PhRMA: Even as biopharma companies commit massive resources to R&D, the industry ranks in the middle for annual issued patents as compa….

Middlemen are driving up the cost of medicine in the U.S.—and patients are paying the price. #PBMs and #340B hospitals secure steep discounts on medicines but patients still have to pay the full price. If we want to lower costs for Americans, we need to rein in PBMs and fix the.

RT @statnews: Policymakers will need to address the true drivers of high drug prices here at home, while simultaneously pressing our allies….

RT @mybarra: Aluminum based adjuvants and thimerosal are the two ingredients often questioned in conversations about #vaccines but the evid….

Being part of an industry that's driving progress in research for diseases like Alzheimer’s is incredibly rewarding. Alzheimer’s doesn't just impact individuals, it affects entire families and communities. This month, I’m reflecting on the importance of the work we do to advance.

President Trump is right: Americans often overpay for medicine, and middlemen are cashing in, pocketing more in rebates and fees than the full prices of drugs in many other countries. Instead of implementing “foreign-first pricing,” here’s how I think we can lower drug prices for

At @semafor’s World Economy Summit, we explored how biopharma innovation is transforming public health, fueling economic growth, and poised to save billions in health care costs. The stakes—and the impact—have never been greater.